incidence
Cancer of the nasopharynx (NPC) is rare in Europe, with an annual crude incidence rate of 1.1 per 100 000. On the European scale, NPC accounts for 4760 new cases per year. Incidence is higher in men than women. [1, 2] .
In Europe, the relative survival for NPC was 76% at 1 year and 50% at 5 years in adults. There were no survival differences between the sexes. The effect of age on survival is marked. Survival at 5 years was 72% for the youngest age group (15-45 years) and 36% in the oldest group of patients (65-74 years) [1, 2] .
diagnosis
Definitive diagnosis is made by endoscopic-guided biopsy of the primary nasopharyngeal tumor. The histological type should be classified according to World Health Organization (WHO) classification [3] . Since the first disease sign in patients is often the appearance of neck nodes it is not infrequent that patients undergo neck biopsy and/or neck nodal dissection. This procedure is not recommended since it may reduce cure probability and have an impact on late treatment sequelae.
staging and risk assessment
NPC is clinically staged according to the International Union Against Cancer (UICC) and American Joint Committee on Cancer (AJCC) staging system ( . RT is targeted to the primary tumor and the adjacent regions considered at risk of microscopic spread from the tumor, and to both the sides of the neck (levels Ib-V, and retropharyngeal nodes). For patients with lower neck nodes, the supraclavicular fossa should be included as well. Elective nodal irradiation is recommended for N0 stage disease. The consensus is that a total dose of 70 Gy is needed for † . This provides a benefit in terms of overall survival and on both locoregional and distant control [9, [11] [12] [13] [14] [15] . While three cycles of adjuvant cisplatin-5FU has been a standard part of many concurrent chemoradiotherapy regimens, its benefit is uncertain and toxic effect is substantial [16] . Cisplatinumbased induction chemotherapy has been shown to improve disease-free survival and may be considered in locally advanced disease although it is not seen as a standard treatment [II, B] [17] . In no case should induction chemotherapy negatively affect the optimal administration of concomitant chemoradiation.
follow-up
Documentation of complete remission in the nasopharynx and neck through clinical and endoscopic examination and/or imaging studies is important. MRI is often used to evaluate the response to RT or chemoradiotherapy, especially for T3 and T4 tumors, though distinction between post-irradiation changes and recurrent tumors may be difficult. Follow-up for patients includes periodic examination of the nasopharynx and neck, cranial nerve function and evaluation of systemic complaints to identify distant metastasis. For T3 and T4 tumors, MRI might be used on a 6-to 12-month basis to evaluate the nasopharynx and the base of the skull at least for the first few years after treatment. Evaluation of thyroid function in patients with irradiation to the neck is recommended at 1, 2 and 5 years. Tumor with intracranial extension and/or involvement of cranial nerves, hypopharynx, orbit, or with extension to the infratemporal fossa/masticator space Regional lymph nodes (N)
N1
Unilateral metastasis in cervical lymph node(s), ≤6 cm in greatest dimension, above the supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal lymph nodes, ≤6 cm, in greatest dimension N2
Bilateral metastasis in cervical lymph node(s), ≤6 cm in greatest dimension, above the supraclavicular fossa N3
Metastasis in a lymph node(s) >6 cm and/or to supraclavicular fossa N3a >6 cm in dimension N3b
Extension to the supraclavicular fossa Tis  N0  M0  Stage I  T1  N0  M0  Stage II  T1  N1  M0  T2  N0  M0  T2  N1  M0  Stage III  T1  N2  M0  T2  N2  M0  T3  N0  M0  T3  N1  M0  T3  N2  M0  Stage IVA  T4  N0  M0  T4  N1  M0  T4  N2 
